重用葡萄糖类-1受体激动剂用于治疗神经退行性疾病
Marwan N Sabbagh1, Jeffrey L Cummings2, Clive Ballard3
1Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA. marwan.sabbagh@barrowneuro.org.
Nature aging
|December 19, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 在阿尔茨海默氏病 (AD) 治疗方面表现有前途. 这些用于糖尿病的药物可能会降低痴呆风险和神经炎症,因此需要进一步研究AD.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 治疗方法正在发展,超出了粉样蛋白标.
- 神经炎症是神经退行性疾病的关键病理标志.
- 现有的抗炎疗法对阿尔茨海默氏症的治疗方法表现出有限的成功.
研究的目的:
- 审查葡萄糖类-1受体激动剂 (GLP-1RAs) 作为阿尔茨海默病治疗策略的潜力.
- 探索GLP-1RA在神经退行性疾病中的疗效机制基础.
- 总结目前支持GLP-1RA在AD治疗中的证据.
主要方法:
- 对连接GLP-1RA使用与降低痴呆风险的流行病学数据的审查.
- 检查表明GLP-1RA对神经炎症的影响的临床前研究.
- 对GLP-1RAs在轻度认知障碍和轻度AD痴呆症中的临床试验结果的分析.
主要成果:
- 流行病学研究表明,GLP-1RA使用与2型糖尿病和心血管疾病患者全因痴呆风险较低有关.
- 临床前模型显示GLP-1RAs可以减轻神经炎症过程.
- 目前的临床试验尚未证实GLP-1RAs在AD早期的认知益处.
结论:
- GLP-1RAs代表了治疗神经退行性疾病,特别是AD的一类有前途的药物.
- 需要进一步的临床研究来确定GLP-1RAs在减缓阿尔茨海默氏症认知衰退方面的有效性.
- GLP-1RAs通过向神经炎症和其他机制,为AD治疗提供了潜在的新途径.
相关概念视频
01:24Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:15Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
01:24Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K